By Fineline Cube 
InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of 2026 on Aug. 25, posting total revenue of RMB 1.14 billion, up 55.5% year‑on‑year, and a net profit of RMB 240 million — turning losses into profits compared with the same period last year.
H1 2026 Financial Highlights
| Item | 2026 H1 | YoY Change |
|---|---|---|
| Total Revenue | RMB 1.14 billion | +55.5% |
| Drug Revenue | RMB 920 million | +43.2% |
| Net Profit | RMB 240 million | Turned profitable YoY |
Revenue Drivers
- Orelabrutinib (BTK inhibitor): The flagship product remained the primary growth engine, sustaining rapid commercial expansion.
- Tafasitamab (CD19 monoclonal antibody): Approved in 2025, contributing incremental revenue during the reporting period.
- Zurletrectinib (TRK inhibitor): The second 2025‑approved innovative drug also added to drug sales, broadening InnoCare’s commercialized portfolio.
Regulatory & Pipeline Milestones
- Orelabrutinib – Australia: Received marketing approval in Australia during the reporting period, extending the drug’s international footprint.
- Orelabrutinib – ITP (China): The New Drug Application (NDA) for the treatment of primary immune thrombocytopenia (ITP) was accepted by China’s National Medical Products Administration (NMPA) — a key milestone marking the drug’s expansion from hematological oncology into autoimmune diseases, with potential to address the treatment needs of more patients.
- Zurletrectinib – Pediatric Solid Tumors (China): The NDA in pediatric solid tumors was also accepted by the NMPA, potentially widening the TRK inhibitor’s indication coverage.
Strategic Outlook
- Path to Sustainable Profitability: The swing to a RMB 240 million net profit underscores InnoCare’s transition from a development‑stage biotech to a commercial‑phase company, underpinned by double‑digit revenue growth.
- Portfolio Diversification: With three marketed innovative drugs and orelabrutinib’s push into autoimmune indications, InnoCare is building a broader commercial base beyond its oncology core.
- Label Expansion: Acceptance of the ITP and pediatric solid tumor NDAs sets the stage for additional launches in China, reinforcing the company’s long‑term growth trajectory.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding InnoCare Pharma’s financial performance, regulatory approvals and commercialization prospects. Actual results may differ due to risks including clinical outcomes, regulatory decisions, market adoption and competitive dynamics.-Fineline Info & Tech